Research Article

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Table 2

Baseline characteristics ( ).

Characteristics (%)Median (range)

Age, years71 (65–92)
 65–7493 (73.2%)
7534 (26.8%)
Sex
 Male62 (48.8%)
 Female65 (51.2%)
ECOG
 0-1 74 (58.3%)
252 (40.9%)
 Unknown1 (0.8%)
Durie-Salmon stage
 110 (7.9%)
 228 (22.0%)
 389 (70.1%)
International staging system
 123 (18.1%)
 251 (40.2%)
 347 (37.0%)
 Unknown6 (4.7%)
Lytic bone lesion
 Yes112 (88.2%)
 No14 (11.0%)
Hemoglobin (g/dL)9.66 (5.20–16.30)
1075 (59.1%)
1052 (40.9%)
Platelets (×109/L) 195 (44–484)
100 11 (8.7%)
100 117 (91.3%)
Plasma cells in bone marrow (%)43.88 (1.10–100)
4058 (45.7%)
4065 (51.2%)
Serum calcium (mg/dL)9.35 (7.00–15.70)
11.511 (8.7%)
11.5115 (90.6%)
Serum albumin (mg/dL)3.28 (1.70–4.80)
3.5 85 (66.9%)
3.5 42 (33.1%)
eGFR (mL/min/1.73 m2)66.60 (5.90–170.5)
30 112 (88.2%)
3015 (11.8%)
Serum LD
UNL27 (21.3%)
UNL74 (58.3%)
Initial chemotherapy regimen
 Conventional (CP, MP, and others)92 (78.0%)
 Novel agents (imid, bortezomib-based)26 (22.0%)
Treatment
 Chemotherapy118 (92.9%)
 No chemotherapy9 (7.1%)

ECOG, eastern cooperative oncology group; eGFR, estimated glomerular filtration rate; LD, lactate dehydrogenase; UNL, upper normal limit; CP, cyclophosphamide and prednisolone; MP, melphalan and prednisolone.